FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3106837305> ?p ?o ?g. }

• W3106837305 abstract "Rheumatoid arthritis (RA) is a chronic autoimmune condition manifested by synovial inflammation and joint destruction and is associated with high morbidity and mortality. While the existing biologic therapies revolutionised the management of RA, considerable unmet needs in disease management require the development of new therapeutic agents. Janus kinases (JAKs) are intracellular tyrosine kinases employed by Type I and Type II cytokine receptors and transducing the signals from a range of cytokines and growth factors. They are indispensable in mediating the signaling of inflammatory cytokines implicated in the pathogenesis of autoimmune conditions, thus present attractive targets for therapeutic intervention. Tofacitinib was the first JAK inhibitor approved for the treatment of RA, which was effective in patients refractory to existing treatments. Among its immunomodulatory mechanisms, tofacitinib was reported to impair the proliferation, differentiation, and pro-inflammatory cytokine production in CD4+ T cells, both in vitro and in vivo. However, the impact of tofacitinib as well as the stage of the drug interference (priming or re-activation) on cognate CD4+ T cell-dendritic cell (DC) interaction, which underlies both breakdown of self-tolerance and autoimmune response propagation in RA, remains to be elucidated. Using the antigen-specific cell system both in vitro and in vivo, I have shown that tofacitinib treatment impaired the priming of the CD4+ T cells by DCs, resulting in their diminished ability to differentiate into T helper 1 (Th1) subset and exhibit associated T-bet expression and IFNy production. This effect on CD4+ T cells was observed both in vitro and in vivo and persisted upon secondary antigenic challenge. On the contrary, the antigen-experienced CD4+ T cells primed in the absence of tofacitinib retained their functional capacity upon re-activation in the presence of the drug. Tofacitinib efficacy assessment in the mouse model of early RA similarly revealed that the antigen-experienced CD4+ T lymphocytes, from both adoptively transferred and endogenous populations, remained unaffected by tofacitinib treatment. While JAK inhibitor had no impact on paw thickness, it induced notable (although non-significant) improvement in features of joint pathology, which, together with the absence of effect on CD4+ T lymphocytes, suggested tofacitinib targeting other inflammatory cells contributing to the autoimmune response. Overall, these results have shown that tofacitinib interferes with the naive CD4+ T cell differentiation into the Th1 subset, thereby indicating a mechanism by which tofacitinib might in part achieve clinical efficacy in RA patients. The antigen-specific system and early RA mouse model are warranted as useful platforms for further investigation of tofacitinib immunomodulatory mechanisms with the view of the optimization of its clinical use." @default.
• W3106837305 created "2020-12-07" @default.
• W3106837305 creator A5036047277 @default.
• W3106837305 date "2020-01-01" @default.
• W3106837305 modified "2023-09-23" @default.
• W3106837305 title "Investigating the impact of JAK inhibitor tofacitinib on the CD4+ T cell-dendritic cell interactions in murine models of rheumatoid arthritis" @default.
• W3106837305 hasPublicationYear "2020" @default.
• W3106837305 type Work @default.
• W3106837305 sameAs 3106837305 @default.
• W3106837305 citedByCount "0" @default.
• W3106837305 crossrefType "dissertation" @default.
• W3106837305 hasAuthorship W3106837305A5036047277 @default.
• W3106837305 hasConcept C112392421 @default.
• W3106837305 hasConcept C203014093 @default.
• W3106837305 hasConcept C2776090121 @default.
• W3106837305 hasConcept C2777077863 @default.
• W3106837305 hasConcept C2777575956 @default.
• W3106837305 hasConcept C2778690821 @default.
• W3106837305 hasConcept C2778886723 @default.
• W3106837305 hasConcept C502942594 @default.
• W3106837305 hasConcept C71924100 @default.
• W3106837305 hasConcept C8891405 @default.
• W3106837305 hasConceptScore W3106837305C112392421 @default.
• W3106837305 hasConceptScore W3106837305C203014093 @default.
• W3106837305 hasConceptScore W3106837305C2776090121 @default.
• W3106837305 hasConceptScore W3106837305C2777077863 @default.
• W3106837305 hasConceptScore W3106837305C2777575956 @default.
• W3106837305 hasConceptScore W3106837305C2778690821 @default.
• W3106837305 hasConceptScore W3106837305C2778886723 @default.
• W3106837305 hasConceptScore W3106837305C502942594 @default.
• W3106837305 hasConceptScore W3106837305C71924100 @default.
• W3106837305 hasConceptScore W3106837305C8891405 @default.
• W3106837305 hasLocation W31068373051 @default.
• W3106837305 hasOpenAccess W3106837305 @default.
• W3106837305 hasPrimaryLocation W31068373051 @default.
• W3106837305 hasRelatedWork W1487885191 @default.
• W3106837305 hasRelatedWork W1554927065 @default.
• W3106837305 hasRelatedWork W1596314149 @default.
• W3106837305 hasRelatedWork W1909485969 @default.
• W3106837305 hasRelatedWork W2160414772 @default.
• W3106837305 hasRelatedWork W2190372139 @default.
• W3106837305 hasRelatedWork W2215521920 @default.
• W3106837305 hasRelatedWork W2409683433 @default.
• W3106837305 hasRelatedWork W2460380501 @default.
• W3106837305 hasRelatedWork W2541126885 @default.
• W3106837305 hasRelatedWork W2738325237 @default.
• W3106837305 hasRelatedWork W2750144808 @default.
• W3106837305 hasRelatedWork W2770663599 @default.
• W3106837305 hasRelatedWork W2987104954 @default.
• W3106837305 hasRelatedWork W3030967916 @default.
• W3106837305 hasRelatedWork W3045620684 @default.
• W3106837305 hasRelatedWork W3084498128 @default.
• W3106837305 hasRelatedWork W3098466838 @default.
• W3106837305 hasRelatedWork W3115951749 @default.
• W3106837305 hasRelatedWork W3120044024 @default.
• W3106837305 isParatext "false" @default.
• W3106837305 isRetracted "false" @default.
• W3106837305 magId "3106837305" @default.
• W3106837305 workType "dissertation" @default.